| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI149839 | Engineering a potent immune-evading uricase | 000 | 2 | NIH | 1/3/2023 | -$44,211 |
| | 2023 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI149839 | Engineering a Potent Immune-evading Uricase | 000 | 1 | NIH | 1/3/2023 | $44,211 |
|
| Issue Date FY: 2022 ( Subtotal = -$1,000,000 ) |
| | 2022 | 2021 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI149839 | Engineering a potent immune-evading uricase | 000 | 2 | NIH | 4/7/2022 | -$1,000,000 |
| | 2022 | 2021 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI149839 | Engineering a potent immune-evading uricase | 001 | 2 | NIH | 8/16/2022 | $44,211 |
| | 2022 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI149839 | Engineering a Potent Immune-evading Uricase | 000 | 1 | NIH | 8/16/2022 | -$44,211 |
| | 2022 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI150235 | Deimmunized Griffithsin Microbicide | 000 | 1 | NIH | 6/15/2022 | $0 |
| | 2022 | 2019 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R41AI142940 | Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage. | 000 | 1 | NIH | 10/14/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,000,000 ) |
| | 2021 | 2021 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI149839 | Engineering a potent immune-evading uricase | 000 | 2 | NIH | 2/26/2021 | $1,000,000 |
| | 2021 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI150235 | Deimmunized Griffithsin Microbicide | 000 | 1 | NIH | 1/6/2021 | $0 |
| | 2021 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI149839 | Engineering a Potent Immune-evading Uricase | 000 | 1 | NIH | 1/5/2021 | $0 |
| | 2021 | 2020 | STEALTH BIOLOGICS, LLC | 16 CAVENDISH CT | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI149839 | Engineering a Potent Immune-evading Uricase | 001 | 1 | NIH | 2/26/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $599,145 ) |
| | 2020 | 2020 | STEALTH BIOLOGICS LLC | 16 CAVENDISH CT RM 229 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R43AI149839 | Engineering a Potent Immune-evading Uricase | 000 | 1 | NIH | 12/18/2019 | $299,870 |
| | 2020 | 2020 | STEALTH BIOLOGICS LLC | 16 CAVENDISH CT RM 229 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R44AI150235 | Deimmunized Griffithsin Microbicide | 000 | 1 | NIH | 12/20/2019 | $299,275 |
| | 2020 | 2019 | STEALTH BIOLOGICS LLC | 16 CAVENDISH CT RM 229 | LEBANON | NH | 03766-1441 | GRAFTON | USA | R41AI142940 | Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage. | 000 | 1 | NIH | 5/13/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $284,815 ) |
| | 2019 | 2019 | STEALTH BIOLOGICS LLC | 201 DORCHESTER RD | LYME | NH | 03768-3814 | GRAFTON | USA | R41AI142940 | Improving HSV-2 vaccine efficacy by focusing antibody epitope coverage. | 000 | 1 | NIH | 4/17/2019 | $284,815 |
|
| Issue Date FY: 2015 ( Subtotal = $185,930 ) |
| | 2015 | 2015 | STEALTH BIOLOGICS LLC | 201 DORCHESTER ROAD | LYME | NH | 03768 | GRAFTON | USA | R41AI118133 | Design and Development of Immunotolerant S. aureus Biotherapies | 000 | 1 | NIH | 2/2/2015 | $185,930 |
|
|
